Phase 3 Readout

PDSB: Phase 3 Topline: A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-

Name: Phase 3 Topline: A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-
Start: 2029-02-01
End: 2029-02-01

February 1, 2029 · pds0101. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: February 1, 2029
Company: PDS Biotechnology Corp (PDSB)
Drug: pds0101

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-

February 1, 2029

PDSB overview →

Company: PDS Biotechnology Corp (PDSB)
Drug: pds0101
Indication: Unresectable Head and Neck Squamous Cell Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Neoplasms, Head and Neck